每个试剂盒可转染的孔数（6孔板）

9

3

3

转染次数

4

6-8

6-8

获得原代iPS细胞克隆所需天数

10-14

12-14

12-14

重编程效率

2-+4%

0.1-0.5%

0.4-3%

筛选

否

否

否

兼容异源成分的培养步骤

是

否

否

GMP级的RNA制备步骤

是

是

是

试剂盒组分

 OKSMNL NM-RNA（编号05-0040），30 µg，1 vial
 EKB NM-RNA（编号05-0041），22 µg，1 vial
 NM-microRNAs（编号05-0042），15 µg，1 vial

储存与稳定性

 1. 试剂盒三种成分均需储存在-70°C以下；
 2. 在适当的保存条件下，自到货后三个月内有效。

质量控制

 试剂盒种每种mRNA的大小与完整性均经过检测。

 StemRNA 3rd Gen Reprogramming Kit 成功进行了人成纤维细胞和人脐静脉内皮细胞RNA基础重编程功能验证。

 iPS细胞系完全重编程可通过多能性标记物的表达及正确的形态来确认。

 试剂盒所有组分均无菌，支原体检测均呈阴性。

使用许可

 该产品使用Biontech AG独家许可技术，引自专利WO 2009/088134。

 Biontech AG的WO 2007/036366，WO 2007/036366，WO 2007/036366和WO 2007/036366等多专利也涵盖

 了本产品。

尿液-Protocol

成纤维细胞-Protocol

Featured Publication

2.

Gagliano O; Luni C; Qui W; Bertin E; Torchio E; Galvanin S; Urciuolo A; Elvassore N. Microfluidic reprogramming to pluripotency of human somatic cells. Nat. Protocols 14:772-737 (2019).

The StemRNA 3rd Gen Reprogramming Kit was used to generate iPSCs from fibroblasts in a microfluidic system that used only 1500 cells in 20 µL of medium. RNA-based reprogramming is ideal for such an application since it does not require extended culture for elimination of reprogramming vectors.

Additional Publications

3.

Nakajima M; Yoshimatsu S; Sato T; Nakamura M; Okahara J; Sasaki E; Shiozawa S; Okano H. Establishment of induced pluripotent stem cells from common marmoset fibroblasts by RNA-based reprogramming. Biochem Biophys Research Commun in press:

https://doi.org/10.1016/j.bbrc.2019.05.175 (2019).

4.

Watanabe T; Yamazaki S; Yoneda N; Shinohara H; Tomioka I; Iiguchi T; Tagoto M; Ema M; Suemizu H; Kawai K; Sasaki E. Highly efficient induction of primate iPS cells by combining RNA transfection and chemical compounds. Genes to Cells in press:doi:10.1111/gtc.12702 (2019).

5.

Liu L-P; Li Y-M; Guo N-N; LI S; Ma X; Zhang Y-X; Gao Y; Huang J-L; Zheng D-X; Wang L-Y; Xu H; Hui L; Zheng Y-W. Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous Transplantation. Cell Reports 27:455-466.e5 (2019).

6.

Sacco AM; Belviso I; Romano V; Carfora A; Schonauer F; Nurzynska D; Montagnani S; Di Meglio F; Castaldo C. Diversity of dermal fibroblasts as major determinant of variability in cell reprogramming. J Cell Mol Med :1-13; https://doi.org/10.1111/jcmm.14316 (2019).

7.

Klein T; Klug K; Henkel L; Kwok CK; Edenhofer F; Klopocki E; Kurth I; Üceyler N. Generation of two induced pluripotent stem cell lines from skin fibroblasts of sisters carrying a c.1094C>A variation in the SCN10A gene potentially associated with small fiber neuropathy. Stem Cell Res 35:101396 (2019).

8.

Dasgupta B; Rusha E; Drukker M. iPSC generation, prime to naïve reversion & characterization and primordial germ cell differentiation of Northern White Rhino. Univ Bremen : (2019).

9.

Su S; Guntur AR; Nguyen DC; Fakory SS; Doucette CC; Leech C; Lotana H; Kelley M; Kohil J; Martino J; Sims-Lucas S; Liaw L; Vary C; Rosen CJ; Brown AC. A Renewable Source of Human Beige Adipocytes for Development of Therapies to Treat Metabolic Syndrome. Cell Reports 25:3215-3228.e9 (2018).

10.

Klein T; Henkel L; Klug K; Kwok CK; Klopocki E; Üceyler N. Generation of the human induced pluripotent stem cell line UKWNLi002-A from dermal fibroblasts of a woman with a heterozygous c.608 C>T (p.Thr203Met) mutation in exon 3 of the nerve growth factor gene potentially associated with hereditary sensory and autonomic neuropathy type 5. Stem Cell Research

https://doi.org/10.1016/j.scr.2018.10.017 (2018)

11.

Liu X; Nefzger CM; Rossello FH; Chen J; Knaupp AS; Firas J; Ford E; Pflueger J; Paynter JM; Chy HS; O'Brien CM; Huang C; Mishra K; Hodgson-Garms M; Jansz N; Williams SM; Blewitt ME; Nilsson SK; Schittenhelm RL; Laslett AL; Lister R; Polo JM. Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming. Nature Methods 14:1055 (2017)